GWP
CORT icon

Gen-Wealth Partners’s Corcept Therapeutics CORT Stock Holding History

Gen-Wealth Partners’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,325
Closed -$66.8K – 633
2024
Q4 		$66.8K Buy
+1,325
New +$69.4K 0.03% 337

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Gen-Wealth Partners's CORT Position: Q1 2025 in Review

Gen-Wealth Partners sold out of Corcept Therapeutics (CORT) in Q1 2025, closing a stake of 1,325 shares — an estimated $66.8K sold.

Gen-Wealth Partners first reported a position in CORT in Q4 2024 and held it in 1 quarter. The position peaked at $66.8K in Q4 2024. 422 funds tracked by Wall St. Rank hold CORT as of Q1 2025.

  • Gen-Wealth Partners reported no remaining Corcept Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Gen-Wealth Partners sold 1,325 Corcept Therapeutics shares in Q1 2025, an estimated $66.8K.
  • Gen-Wealth Partners first reported a position in Corcept Therapeutics in Q4 2024 and held it in 1 quarter.
  • Gen-Wealth Partners's Corcept Therapeutics position peaked at $66.8K in Q4 2024.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2025.

Based on Gen-Wealth Partners's 13F filing for Q1 2025, filed 13 May 2025.